Ad
related to: why xeloda for breast cancer risk
Search results
Results from the WOW.Com Content Network
Capecitabine, sold under the brand name Xeloda among others, is a anticancer medication used to treat breast cancer, gastric cancer and colorectal cancer. [3] For breast cancer it is often used together with docetaxel. [4] It is taken by mouth. [4] Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. [4]
Last week, Israel-based Teva Pharmaceuticals' generic product portfolio received a major boost after the Food and Drug Administration approved the company's generic version of Xeloda, a cancer drug.
During the 20-year study period, 8.5 percent of women who had lumpectomies died from breast cancer, nine percent of women who had mastectomies died from the disease, and 8.5 percent of women who ...
Moreover, breast cancer risk is heightened following use of the combined oral contraceptive pill and combined hormone replacement therapy. [4] Armed with this evidence that endogenous and exogenous changes in estrogen and progesterone levels modulate the risk of breast cancer, it is apparent that hormones can play a key role in breast cancer.
In March 2007, the U.S. Food and Drug Administration (FDA) approved lapatinib in combination therapy for breast cancer patients already using capecitabine (Xeloda). [4] [5] In January 2010, Tykerb received accelerated approval for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor and for whom hormonal therapy is ...
Recurrence risk “The risk of breast cancer is very individualized, and depends on many factors,” says Dr. Eleonora Teplinsky, clinical assistant professor of medicine at Icahn School of ...
Staging breast cancer is the initial step to help physicians determine the most appropriate course of treatment. As of 2016, guidelines incorporated biologic factors, such as tumor grade, cellular proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression profiling into the staging system.
Harmful mutations in BRCA2 - a gene responsible for repairing damaged DNA - significantly increase the risk of breast, ovarian, prostate and pancreatic cancers. About 45% of women who inherit a ...
Ad
related to: why xeloda for breast cancer risk